KUALA LUMPUR, Aug 18: An artificial intelligence (AI)-powered, non-invasive drug-screening technology, The Instant Visual Drug Detector (IVDD), was showcased at a Royal Malaysia Police (PDRM) seminar here today as a potential tool to support drug prevention and enforcement efforts.
Distributed by XSPec Technology Sdn Bhd, IVDD was showcased at the Seminar on AI Applications in Modern Crime Investigation and National Security 2026, held from Aug 16 to 18 at the PDRM College in Cheras here.
XSPec chief executive officer Sugito Wibawa said the showcase provided participants with first-hand exposure to the AI-enabled technology and its potential applications in supporting drug prevention and enforcement efforts.
He said IVDD has been used to screen more than 1,000 secondary school students and local council employees in Selangor with very encouraging results.
In a statement issued in conjunction with the seminar, he said IVDD combines infrared imaging with artificial intelligence and deep-learning technology to analyse the iris and provide a rapid preliminary screening result.
“Unlike conventional drug screening methods that may require biological samples, IVDD is designed as a non-invasive early screening solution, making it potentially useful in situations where speed, mobility and the screening of larger numbers of individuals are operational considerations.
“The inclusion of IVDD at a seminar focused on the application of AI in modern crime investigation is particularly significant, it demonstrates how emerging technologies can potentially support law enforcement agencies in addressing increasingly complex security and drug-related challenges,” he said.
He said integrating responsible AI technologies into existing enforcement and prevention strategies could contribute to more efficient, data-driven and technology-enabled approaches to combating drug abuse.
“AI should not be viewed as replacing established enforcement procedures. Rather, technologies such as IVDD can complement existing processes by providing officers with an additional screening tool that may assist in identifying cases requiring further assessment and appropriate confirmatory testing,” he added.
— BERNAMA